CTLA4-Ig (Abatacept) Therapy Modulates T Cell Effector Functions in Autoantibody-Positive Rheumatoid Arthritis Patients

BMC Immunology - United Kingdom
doi 10.1186/1471-2172-14-34
Full Text
Abstract

Available in full text

Categories
Immunology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Abatacept: A T-Cell Co-Stimulation Modulator for the Treatment of Rheumatoid Arthritis

Clinical Rheumatology
MedicineRheumatology
2008English

Effects of Abatacept on Monocytes in Patients With Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2010English

T-Cell Aging in Rheumatoid Arthritis

Current Opinion in Rheumatology
Rheumatology
2014English

Successful Treatment of T Cell-Mediated Acute Rejection With Delayed CTLA4-Ig in Mice

Frontiers in Immunology
AllergyImmunology
2017English

ACCLAIM: A Randomized Trial of Abatacept (CTLA4-Ig) for Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis
Neurology
2016English

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

Cell Reports
BiochemistryGeneticsMolecular Biology
2019English

Autoantibody Formation in Patients With Rheumatoid Arthritis Treated With Anti-TNF

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2004English

The Efficacy and Safety of Abatacept in Rheumatoid Arthritis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2010English

Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation—Lessons From Rheumatoid Arthritis

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy